A human antibody including an H chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NOS: 1-3 and an L chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NOS: 4-6. This human antibody is suited to use in humans, and exhibits activity for binding specifically to transthyretin (TTR) which has undergone a structural change and activity for inhibiting fibrosis of TTR.
